Boston Scientific Stresses Cardiology R&D, Makes Over Business Units
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's planned launches of IVUS systems, cutting balloons and embolic protection devices will allow the firm to buttress its drug-eluting stent offering with core cardiovascular growth
You may also be interested in...
Boston Scientific’s Pulse Races At Thought Of CRM Prospects
Confidence in the potential U.S. success of the Taxus paclitaxel-eluting stent is spurring Boston Scientific to charge forward with its long-term growth strategy of expanding the firm's core cardiology business
Boston Scientific’s Pulse Races At Thought Of CRM Prospects
Confidence in the potential U.S. success of the Taxus paclitaxel-eluting stent is spurring Boston Scientific to charge forward with its long-term growth strategy of expanding the firm's core cardiology business
Endosurgery, Vascular Growth Seeded By Boston Scientific; Grissom Hired
Boston Scientific's stake in vascular sealant developers Therus and Sub-Q, Inc. is part of a plan to keep investors focused on growth prospects for the company beyond Taxus' U.S. launch in early 2004